Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China

ConclusionsOverall, this analysis demonstrates that adherence to guideline recommendations of regular molecular monitoring of patients with CML-CP treated with TKIs provides significant clinical benefit that leads to substantial cost savings compared to no molecular monitoring from the perspective of a Chinese payer. In a time where healthcare systems have limited resources to allocate to optimal patient care, investment in molecular monitoring is an ideal choice for improving patient benefits at a reduced cost.

Source: PLoS One - October 25, 2021 Category: Biomedical Science Authors: Vikalp Kumar Maheshwari Source Type: research